V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.93 USD -2.98% Market Closed
Market Cap: 79.3m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

Intrinsic Value

VTGN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VTGN stock under the Base Case scenario is 2.28 USD. Compared to the current market price of 2.93 USD, VistaGen Therapeutics Inc is Overvalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VTGN Intrinsic Value
2.28 USD
Overvaluation 22%
Intrinsic Value
Price
V
Worst Case
Base Case
Best Case

Valuation Backtest
VistaGen Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VTGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VTGN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about VistaGen Therapeutics Inc

Provide an overview of the primary business activities
of VistaGen Therapeutics Inc.

What unique competitive advantages
does VistaGen Therapeutics Inc hold over its rivals?

What risks and challenges
does VistaGen Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in VistaGen Therapeutics Inc recently?

Summarize the latest earnings call
of VistaGen Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for VistaGen Therapeutics Inc.

Provide P/S
for VistaGen Therapeutics Inc.

Provide P/E
for VistaGen Therapeutics Inc.

Provide P/OCF
for VistaGen Therapeutics Inc.

Provide P/FCFE
for VistaGen Therapeutics Inc.

Provide P/B
for VistaGen Therapeutics Inc.

Provide EV/S
for VistaGen Therapeutics Inc.

Provide EV/GP
for VistaGen Therapeutics Inc.

Provide EV/EBITDA
for VistaGen Therapeutics Inc.

Provide EV/EBIT
for VistaGen Therapeutics Inc.

Provide EV/OCF
for VistaGen Therapeutics Inc.

Provide EV/FCFF
for VistaGen Therapeutics Inc.

Provide EV/IC
for VistaGen Therapeutics Inc.

Show me price targets
for VistaGen Therapeutics Inc made by professional analysts.

What are the Revenue projections
for VistaGen Therapeutics Inc?

How accurate were the past Revenue estimates
for VistaGen Therapeutics Inc?

What are the Net Income projections
for VistaGen Therapeutics Inc?

How accurate were the past Net Income estimates
for VistaGen Therapeutics Inc?

What are the EPS projections
for VistaGen Therapeutics Inc?

How accurate were the past EPS estimates
for VistaGen Therapeutics Inc?

What are the EBIT projections
for VistaGen Therapeutics Inc?

How accurate were the past EBIT estimates
for VistaGen Therapeutics Inc?

Compare the revenue forecasts
for VistaGen Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of VistaGen Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of VistaGen Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of VistaGen Therapeutics Inc compared to its peers.

Compare the P/E ratios
of VistaGen Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing VistaGen Therapeutics Inc with its peers.

Analyze the financial leverage
of VistaGen Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for VistaGen Therapeutics Inc.

Provide ROE
for VistaGen Therapeutics Inc.

Provide ROA
for VistaGen Therapeutics Inc.

Provide ROIC
for VistaGen Therapeutics Inc.

Provide ROCE
for VistaGen Therapeutics Inc.

Provide Gross Margin
for VistaGen Therapeutics Inc.

Provide Operating Margin
for VistaGen Therapeutics Inc.

Provide Net Margin
for VistaGen Therapeutics Inc.

Provide FCF Margin
for VistaGen Therapeutics Inc.

Show all solvency ratios
for VistaGen Therapeutics Inc.

Provide D/E Ratio
for VistaGen Therapeutics Inc.

Provide D/A Ratio
for VistaGen Therapeutics Inc.

Provide Interest Coverage Ratio
for VistaGen Therapeutics Inc.

Provide Altman Z-Score Ratio
for VistaGen Therapeutics Inc.

Provide Quick Ratio
for VistaGen Therapeutics Inc.

Provide Current Ratio
for VistaGen Therapeutics Inc.

Provide Cash Ratio
for VistaGen Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for VistaGen Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for VistaGen Therapeutics Inc?

What is the current Free Cash Flow
of VistaGen Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for VistaGen Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
VistaGen Therapeutics Inc

Current Assets 110.8m
Cash & Short-Term Investments 108.4m
Other Current Assets 2.5m
Non-Current Assets 2.7m
PP&E 2.2m
Other Non-Current Assets 518k
Current Liabilities 6.2m
Accounts Payable 1.2m
Accrued Liabilities 2.7m
Other Current Liabilities 2.3m
Non-Current Liabilities 2.5m
Other Non-Current Liabilities 2.5m
Efficiency

Earnings Waterfall
VistaGen Therapeutics Inc

Revenue
972.7k USD
Operating Expenses
-39.1m USD
Operating Income
-38.2m USD
Other Expenses
5m USD
Net Income
-33.2m USD

Free Cash Flow Analysis
VistaGen Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VTGN Profitability Score
Profitability Due Diligence

VistaGen Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Negative Free Cash Flow
Exceptional Revenue Growth Forecast
Negative Operating Income
Negative Net Income
41/100
Profitability
Score

VistaGen Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

VTGN Solvency Score
Solvency Due Diligence

VistaGen Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
64/100
Solvency
Score

VistaGen Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VTGN Price Targets Summary
VistaGen Therapeutics Inc

Wall Street analysts forecast VTGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTGN is 13.26 USD with a low forecast of 12.12 USD and a high forecast of 15.75 USD.

Lowest
Price Target
12.12 USD
314% Upside
Average
Price Target
13.26 USD
353% Upside
Highest
Price Target
15.75 USD
438% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VTGN?

Click here to dive deeper.

Dividends

VistaGen Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VTGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VTGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

VistaGen Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

79.3m USD

Dividend Yield

0%

Description

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Contact

CALIFORNIA
South San Francisco
343 Allerton Ave
+16505773600.0
www.vistagen.com

IPO

2010-10-18

Employees

31

Officers

CEO & Director
Mr. Shawn K. Singh J.D.
VP & Chief Financial Officer
Ms. Cynthia Lynn Anderson CPA
Chief Operating Officer
Mr. Joshua S. Prince M.B.A.
Chief Corporate Development Officer & General Counsel
Mr. Reid G. Adler Esq., J.D.
Senior Vice President of Investor Relations
Mr. Mark Adrian McPartland
Senior Vice President of Human Resources
Ms. Trisha Fitzmaurice
Show More
Senior Vice President of Development Operations
Dr. Allen Easley Cato III, M.D., Ph.D.
Senior VP and Head of Chemistry, Manufacturing & Controls
Dr. Mark J. Ginski Ph.D.
Senior Vice President of Corporate Strategy & Capital Markets
Mr. Mark Flather
Senior Vice President of Global Regulatory Affairs & Pharmacovigilance
Dr. Erik Berglund M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one VTGN stock?

The intrinsic value of one VTGN stock under the Base Case scenario is 2.28 USD.

Is VTGN stock undervalued or overvalued?

Compared to the current market price of 2.93 USD, VistaGen Therapeutics Inc is Overvalued by 22%.

Back to Top